PubMed Journals Articles About "Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017" RSS

03:32 EST 18th February 2019 | BioPortfolio

Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 articles that have been published worldwide.

More Information about "Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017" on BioPortfolio

We have published hundreds of Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 news stories on BioPortfolio along with dozens of Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 Clinical Trials and PubMed Articles about Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 Companies in our database. You can also find out about relevant Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017 Drugs and Medications on this site too.

Showing "Chronic Lymphocytic Leukemia Global Clinical Trials Review 2017" PubMed Articles 1–25 of 54,000+

Histiocytic Sarcoma: Review, Discussion of Transformation From B-Cell Lymphoma, and Differential Diagnosis.

Histiocytic sarcoma is a rare neoplasm of mature histiocytes with an aggressive clinical course that can arise de novo or from a low-grade B-cell lymphoma. In particular, chronic lymphocytic leukemia/small lymphocytic lymphoma is a very common malignancy in the Western hemisphere, and most cases of chronic lymphocytic leukemia/small lymphocytic lymphoma have an indolent course and behavior. However, 2% to 8% of chronic lymphocytic leukemia/small lymphocytic lymphoma cases transform. Histiocytic sarcomatous ...

Antiviral immunity in chronic lymphocytic leukemia measured by anti-rubella antibody.

Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia in Caucasian populations, is characterized by a decrease in anti-infective immunity. Clinical evidence of antiviral immunity decrease is the reactivation of herpes virus in the form of skin lesions. In Europe, rubella infection is common and creates lifelong persistence of IgG antibodies.

A case report of extranodal NK/T-cell lymphoma in patient with chronic lymphocytic leukemia.

Chronic lymphocytic leukemia often results in secondary tumors, the most common being large B cell lymphoma known as Richter syndrome, followed by extranodal NK/T-cell lymphoma (nasal type) is extremely rare.

The Role of miR-15a and miR-16-1 in the Pathogenesis of Chronic Lymphocytic Leukemia, and the Importance of microRNAs in Targeted Therapies.

Chronic lymphocytic leukemia (CLL) is the most common type of hematological cancer diagnosed in human adults; however, it has been linked with a series of chromosomal abnormalities, the most common being deletion of 13q14. This chromosomal alteration leads to the deletion of the miR-15/16 cluster, as well as downregulation of DLEU7. Deletion of miR-15a and miR-16-1 causes overexpression of BCL2, an apoptosis suppressing protein, while the deletion of DLEU7 activates the NF-kB pathway. Both lead to the devel...

Leukemic Involvement in the Thorax.

Leukemias are malignancies in which abnormal white blood cells are produced in the bone marrow, resulting in compromise of normal bone marrow hematopoiesis and subsequent cytopenias. Leukemias are classified as myeloid or lymphoid depending on the type of abnormal cells produced and as acute or chronic according to cellular maturity. The four major types of leukemia are acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Clinical manifestations a...

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3Kδ inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p 65, β2-microglobulin...

Analysis of four types of leukemia using Gene Ontology term and Kyoto Encyclopedia of Genes and Genomes pathway enrichment scores.

Leukemia is the second common blood cancer after lymphoma, and its incidence rate has an increasing trend in recent years. Leukemia can be classified into four types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). More than forty drugs are applicable for different types of leukemia based on the discrepant pathogenesis. Therefore, the identification of specific drug-targeted biological processes and pathways is hel...

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free...

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.

Activation induced deaminase (AID) has two distinct and well defined roles, both relying on its deoxycytidine (dC) deaminating function: one as a DNA mutator and another in DNA demethylation. In chronic lymphocytic leukemia (CLL), AID was previously shown to be an independent negative prognostic factor. While there is substantial impact on DNA mutations, effects of AID on gene expression by promoter demethylation of disease related target genes in leukemia has not been addressed. To shed light on this quest...

Comparison of Tumor Staging Systems for Cutaneous Squamous Cell Carcinoma in Patients with Chronic Lymphocytic Leukemia.

Patients with chronic lymphocytic leukemia (CLL) are at increased risk for poor outcomes as a result of cutaneous squamous cell carcinoma (CSCC).

Research Advances of Monocyte/Macrophage in Chronic Lymphocytic Leukemia--Review.

Chronic lymphocytic leukemia(CLL)is a malignant hematologic disease with heterogeneous clinical course, about two thirds of patients exhibit a long survival, but the remaining third of patients show aggressiveness of disease or poor response to conventional treatment even drug resistance. Studies suggested that tumor microenvironment possesses a critical effect in CLL disease progression in recent years. Monocyte/macrophage, as an important componens of tumor microenvironment, play a promotive role i...

Management of melanoma in patients with chronic lymphocytic leukemia.

Melanoma is significantly more common and is associated with a poorer prognosis in patients with an underlying B-cell malignancy. This study reports on the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) and a subsequent diagnosis of melanoma. In the Wilmot Cancer Institute CLL cohort, which includes 470 patients followed for 2849 person-years, 18 patients (3.8%) developed 22 melanomas. Fourteen melanomas were invasive, a significantly higher rate as compared with t...

Promotion of Japan's participation in global clinical trials.

The number of global clinical trials including Japan is increasing but still much lower than those including the USA and Europe. The regulatory requirements for clinical trials have been harmonized among Japan, USA, and Europe, and the quality of clinical trials is kept high in these regions. Xofluza (baloxavir marboxil) for influenza approved in Japan under the SAKIGAKE Designation System is a good example of clinical trials including Japan. To include Japan in more global clinical trials, stakeholders sho...

Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.

Laboratory testing and treatments for chronic lymphocytic leukemia (CLL) have changed dramatically within the last decade. The authors evaluated changes in patterns of real-world testing and treatment over time by comparing 2 population-based cohorts.

IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.

Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.

Rejection of adoptively transferred Eµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.

Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology annual meeting.

Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology Annual Meeting: commentary.

Remission maintenance treatment options in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) treatment has come a long way in the last two decades, producing increases in tumor control to the point of generating sizeable numbers of patients with undetectable minimal residual disease and creating overall survival benefits in randomized comparisons. Most of this has been achieved by limited-term treatment approaches including chemotherapeutic and immune-therapeutic drugs. More recently, novel therapies targeting signaling pathways essential for the survival of the n...

Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?

Chronic lymphocytic leukaemia (CLL) is 10- to 20-fold less common in Asians (including Han Chinese) compared with persons of predominately European descent. Why is unknown but seems predominately genetic. We observed an increasing frequency of new cases of CLL at our Haematology Centre beginning 2011 and wondered why.

Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.

For patients with chronic myeloid leukemia in chronic phase with sustained deep molecular responses on long-term tyrosine kinase inhibitor (TKI) therapy, treatment-free remission (TFR) feasibility has been established. TFR is now a treatment goal for patients meeting specific criteria; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CML have developed criteria for attempting TFR outside clinical trials, and TFR was added to the US Food and Drug Administration-approved nilotinib label. Im...

Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia.

Peri et al reported a case of invasive aspergillosis with primary pulmonary involvement followed by central nervous system (CNS) involvement in a patient treated for chronic lymphocytic leukemia (CLL) with ibrutinib. In addition to their work, we describe a case of primary CNS aspergillosis involvement and abdominal mucormycosis in a patient treated with ibrutinib. Emerging fungal syndrome in patients with CLL receiving ibrutinib justifies the need for an exhaustive work-up for extrapulmonary involvement an...


to analyze TP53, NOTCH1 and SF3B1 mutations in chronic lymphocytic leukemia (CLL) patients, sufferersof Chornobyl NPP accident to clarify the possible relationship between ionizing radiation (IR) and CLL.

New FDA-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.

Advancements in the treatment of acute myeloid leukemia (AML) have been sparse over the last several decades, and the disease continues to have a poor prognosis. However, in 2017 alone, four new medications approved by the United States Food and Drug Administration (FDA) for the treatment of AML reached the market. Midostaurin, liposomal cytarabine and daunorubicin, enasidenib, and gemtuzumab ogozamicin all showed benefit in respective clinical trials to gain approval for the treatment of AML in various pat...

Quick Search